

Press release from Emotra AB (publ)

Göteborg, July 7, 2021

Emotra is granted patent protection in Canada

EDOR test, Emotra's method for identifying at-risk populations in mental health care, has now secured increased protection in the application area suicide risk following the Canadian Intellectual Property Office's approval of Emotra's patent application with the patent number 2,924,041. Emotra has previously announced that the Company has applied for and been granted patent protection for the same application area in Sweden, the USA and Japan. We have also filed patent applications in the EU.

The Canadian Intellectual Property Office has notified Emotra that their patent application number 2,924,041 with the title "A DEVICE FOR USE IN THE EVALUATION OF SUICIDE RISK" has been approved. The Company has already received patent protection for the same application area in Japan, Sweden and the USA, as well as trademark protection for the EDOR® trademark in the EU.

Daniel Poté, Emotra's CEO, had the following to say:

"Canada, where we have now received approval to use EDOR test to evaluate suicide risk, is an important market for Emotra. Even though the Company has changed its strategic focus to depression relapse, this Canadian approval is very positive news in our drive for patent protection of the EDOR method, now and in the future. So far, the company has not received any serious objections to its patent applications from any patent authority."

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 732 34 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for identifying hyporeactive patients.

Emotra AB, AstraZeneca BioVentureHub, Pepparedsleden 1, SE-431 83 Mölndal, Sweden

Tel: +46 73 234 41 93, www.emotra.se